Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 26-50 of 88 citing articles:

Reappraisal on pharmacological and mechanical treatments of heart failure
Bo Liang, Yu-Xiu Zhao, Xiaoxiao Zhang, et al.
Cardiovascular Diabetology (2020) Vol. 19, Iss. 1
Open Access | Times Cited: 32
Ageing‐associated increase in SGLT2 disrupts mitochondrial/sarcoplasmic reticulum Ca2+ homeostasis and promotes cardiac dysfunction
Yusuf Olğar, Erkan Tuncay, Sinan Değirmenci, et al.
Journal of Cellular and Molecular Medicine (2020) Vol. 24, Iss. 15, pp. 8567-8578
Open Access | Times Cited: 30
Major adverse cardiovascular and limb events in patients with diabetes and concomitant peripheral artery disease treated with sodium glucose cotransporter 2 inhibitor versus dipeptidyl peptidase-4 inhibitor
Hsin‐Fu Lee, Shao‐Wei Chen, Jia‐Rou Liu, et al.
Cardiovascular Diabetology (2020) Vol. 19, Iss. 1
Open Access | Times Cited: 29
Cardiovascular Benefits With Favorable Renal, Amputation and Hypoglycemic Outcomes of SGLT-2 Inhibitors in Type 2 Diabetes From the Asian Perspective: A Population-Based Cohort Study and Systematic Review
Chun‐Ting Yang, Zi‐Yang Peng, Yi‐Chi Chen, et al.
Frontiers in Endocrinology (2022) Vol. 13
Open Access | Times Cited: 17
Cardiovascular, renal, and lower limb outcomes in patients with type 2 diabetes after percutaneous coronary intervention and treated with sodium–glucose cotransporter 2 inhibitors vs. dipeptidyl peptidase-4 inhibitors
Hsin‐Fu Lee, Yi‐Hsin Chan, Chi‐Cheng Chuang, et al.
European Heart Journal - Cardiovascular Pharmacotherapy (2023) Vol. 9, Iss. 4, pp. 301-310
Closed Access | Times Cited: 10
Safety of sodium-glucose transporter 2 (SGLT-2) inhibitors in patients with type 2 diabetes: a meta-analysis of cohort studies
Chun Xing Li, Tian Tian Liu, Qian Zhang, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 10
Prevalence of sodium-glucose transporter 2 inhibitor-associated diabetic ketoacidosis in real-world data: A systematic review and meta-analysis
Bassel Al-Hindi, Mohammed A. Mohammed, Ernest Mangantig, et al.
Journal of the American Pharmacists Association (2023) Vol. 64, Iss. 1, pp. 9-26.e6
Closed Access | Times Cited: 9
Kidney Disease Biomarkers Improve Heart Failure Risk Prediction in the General Population
Christoph Nowak, Johan Ärnlöv
Circulation Heart Failure (2020) Vol. 13, Iss. 8
Open Access | Times Cited: 25
Efficacy of Once-Weekly Semaglutide vs Empagliflozin Added to Metformin in Type 2 Diabetes: Patient-Level Meta-analysis
Ildiko Lingvay, Matthew Capehorn, Andrei‐Mircea Catarig, et al.
The Journal of Clinical Endocrinology & Metabolism (2020) Vol. 105, Iss. 12, pp. e4593-e4604
Open Access | Times Cited: 21
Growing role of SGLT2i in heart failure: evidence from clinical trials
Ajay Varadhan, Katarina Stephan, Rahul Gupta, et al.
Expert Review of Clinical Pharmacology (2022) Vol. 15, Iss. 2, pp. 147-159
Closed Access | Times Cited: 13
The present and future scope of real‐world evidence research in diabetes: What questions can and cannot be answered and what might be possible in the future?
Francesco Zaccardi, Melanie J. Davies, Kamlesh Khunti
Diabetes Obesity and Metabolism (2020) Vol. 22, Iss. S3, pp. 21-34
Open Access | Times Cited: 20
Comparison of heart failure risk and medical costs between patients with type 2 diabetes mellitus treated with dapagliflozin and dipeptidyl peptidase-4 inhibitors: a nationwide population-based cohort study
Jong-Mi Seong, Jong Joo Kim, Hae Jin Kim, et al.
Cardiovascular Diabetology (2020) Vol. 19, Iss. 1
Open Access | Times Cited: 19
Contemporary use of SGLT2 inhibitors in heart failure patients with diabetes mellitus: a comparison of DPP4 inhibitors in a nationwide electric health database of the superaged society
Michikazu Nakai, Yoshitaka Iwanaga, Koshiro Kanaoka, et al.
Cardiovascular Diabetology (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 11
Key results from observational studies and real‐world evidence of sodium‐glucose cotransporter‐2 inhibitor effectiveness and safety in reducing cardio‐renal risk
Thomas Nyström
Diabetes Obesity and Metabolism (2024)
Open Access | Times Cited: 2
Benefit and Safety of Sodium-Glucose Co-Transporter 2 Inhibitors in Older Patients with Type 2 Diabetes Mellitus
Ja Young Jeon, Dae Jung Kim
Diabetes & Metabolism Journal (2024) Vol. 48, Iss. 5, pp. 837-846
Closed Access | Times Cited: 2
SGLT2 inhibitors for prevention of cardiorenal events in people with type 2 diabetes without cardiorenal disease: A meta-analysis of large randomized trials and cohort studies
Mei Qiu, Liang‐Liang Ding, Miao Zhang, et al.
Pharmacological Research (2020) Vol. 161, pp. 105175-105175
Closed Access | Times Cited: 16
Anti-Diabetic Therapy, Heart Failure and Oxidative Stress: An Update
Ioanna Koniari, Dimitrios Velissaris, Nicholas G. Kounis, et al.
Journal of Clinical Medicine (2022) Vol. 11, Iss. 16, pp. 4660-4660
Open Access | Times Cited: 10
Cardiovascular and renal outcomes with SGLT2 inhibitors: Real-life observational studies in older patients with type 2 diabetes
André Scheen
Diabetes Epidemiology and Management (2023) Vol. 10, pp. 100135-100135
Open Access | Times Cited: 6
Transparency in real‐world evidence (RWE) studies to build confidence for decision‐making: Reporting RWE research in diabetes
Elisabetta Patorno, Sebastian Schneeweiß, Shirley Wang
Diabetes Obesity and Metabolism (2020) Vol. 22, Iss. S3, pp. 45-59
Open Access | Times Cited: 15
Cardiovascular morbidity and mortality in patients with type 2 diabetes using novel antidiabetic medicines as add-on therapy: an observational real-world study
Špela Žerovnik, Mitja Kos, Igor Locatelli
BMJ Open (2021) Vol. 11, Iss. 9, pp. e051549-e051549
Open Access | Times Cited: 13
Real-world evaluation of sodium-glucose co-transporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors for managing type 2 diabetes mellitus: a retrospective multi-ethnic cohort study
Louise Gek Huang Goh, Jiandong Sun, Benjamin Shao Kiat Ong, et al.
Journal of Diabetes & Metabolic Disorders (2022) Vol. 21, Iss. 1, pp. 521-555
Open Access | Times Cited: 9
Comparison of Serum Ketone Levels and Cardiometabolic Efficacy of Dapagliflozin versus Sitagliptin among Insulin-Treated Chinese Patients with Type 2 Diabetes Mellitus
Chi‐Ho Lee, Mei‐Zhen Wu, David Tak Wai Lui, et al.
Diabetes & Metabolism Journal (2022) Vol. 46, Iss. 6, pp. 843-854
Open Access | Times Cited: 9
Sodium‐glucose co‐transporter‐2 inhibitors in type 2 diabetes: Are clinical trial benefits for heart failure reflected in real‐world clinical practice? A systematic review and meta‐analysis of observational studies
William Hinton, Abdus Samad Ansari, Martin Whyte, et al.
Diabetes Obesity and Metabolism (2022) Vol. 25, Iss. 2, pp. 501-515
Closed Access | Times Cited: 9
Risk of lower limb amputation in diabetic patients using SGLT2 inhibitors versus DPP4 inhibitors or GLP-1 agonists: a meta-analysis of 2 million patients
Yang Lü, Caiyun Guo
Therapeutic Advances in Drug Safety (2023) Vol. 14
Open Access | Times Cited: 5
Lower-limb amputations in patients treated with SGLT2 inhibitors versus DPP-4 inhibitors: A meta-analysis of observational studies
André Scheen
Diabetes Epidemiology and Management (2022) Vol. 6, pp. 100054-100054
Open Access | Times Cited: 8

Scroll to top